Open Nav

Please submit your session questions in advance at

Reshaping Tumor Microenvironments via Immunotherapies

Current CAR-T therapies have shown significant benefits attacking hematological malignancies, and currently approved checkpoint inhibitors are highly but selectively effective in their impact on solid tumors. This session will examine the next wave of innovation in immunotherapies for leveraging knowledge of how tumor microenvironments develop to create treatments able to demonstrate more durable effects on shrinking tumors across wider ranges of patients.

Moderator: Jotin Marango, MD, PhD, Managing Directior, Sr. Research Analyst, Roth Capital Partners, LLC

  • Date:Monday, February 11
  • Time:9:00 AM - 9:55 AM
  • Room:Shubert Complex
  • Location:6th Floor
  • Session Type:Educational Panel
  • Please submit your session questions in advance:

    Click here.

Jotin Marango
ROTH Capital Partners
Lewis H. Bender
Intensity Therapeutics
Sabine Chlosta
Gere diZerega
Eric Falcand